Brussels: The European Union has taken a significant step in strengthening its preparedness for potential flu pandemics by signing a new joint procurement contract. This agreement, facilitated by the European Commission through the Health Emergency Preparedness and Response Authority, enables 17 countries to purchase up to 27,403,200 pandemic influenza vaccine doses.
According to Cyprus News Agency, the contract was concluded with the pharmaceutical company Seqirus UK Ltd. to secure supplies of Foclivia, a vaccine designed to offer protection when a flu pandemic is declared by the World Health Organization or the European Union. This initiative is part of the Commission’s broader strategy to enhance EU-level preparedness and response capabilities to safeguard public health.
The joint procurement framework builds on previous agreements with CSL Seqirus in 2019 and GSK in 2022. It allows participating countries to access vaccine doses in the event of an influenza pandemic. The framework contract is set for 48 months and includes provisions for two potential 12-month renewals.
The EU’s commitment to a resilient and responsive European Health Union is evident in its strategy to tackle emerging health threats. The Joint Procurement Agreement for Medical Countermeasures, signed by 38 countries, including all EU and EEA Member States, underpins this effort. This mechanism facilitates the voluntary joint procurement of essential medical countermeasures, thereby boosting equitable access and enhancing supply security amidst health threats.
The urgency of this initiative is underscored by the lessons learned from the COVID-19 pandemic, which highlighted the necessity for coordinated responses to cross-border health challenges. The EU continues to prioritize ensuring timely access to medical countermeasures as a critical component of its Preparedness Union strategy.